Tivic Expands Bioelectronic Portfolio; Files Patent Application for New Approach to Non-Invasive Vagus Nerve Stimulation
11 Abril 2023 - 10:00AM
Business Wire
Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a
commercial-phase health technology company that develops and
commercializes bioelectronic medicine, today announced that it has
filed its first patent in Vagus Nerve Stimulation with the U.S.
Patent Office (USPTO), expanding its intellectual property
portfolio into new clinical targets.
Tivic’s prior patents and current products have focused on the
trigeminal and sympathetic nerve structures. The company’s new
filing addresses a novel approach on the state of the art for
non-invasive Vagus Nerve Stimulation (nVNS). It includes a novel
circuit design for more precise targeting of the signals carried by
the vagus nerve, with the potential to offer superior efficacy to
alternative nVNS approaches.
Vagus nerve stimulation is of high interest in medicine due to
its therapeutic and commercial promise. Originating from the human
brainstem, the vagus nerve connects the brain to many vital organs,
including the heart, lungs, and immune system organs such as the
spleen. The vagus nerve is responsible for the regulation of organ
function, carrying sensory information, controlling muscles, and
influencing the immune system. Vagus nerve stimulation has been
proven effective for conditions including treatment-resistant
depression, epilepsy, and migraine.
“Non-invasive stimulation with precision targeting of the vagus
nerve is directly in support of our strategic goals to expand our
proprietary footprint in bioelectronic medicine,” said Jennifer
Ernst, CEO of Tivic. “This patent could advance the field of
bioelectronic medicine with a more precise approach to the
treatment of cardiovascular, neurological/psychiatric, and systemic
inflammatory chronic health conditions without surgery, implants,
or pharmaceuticals.”
Tivic currently has five issued U.S. patents, 96 claims, and 20
pending patents in the U.S. and abroad.
Its first commercial product, ClearUP, is an over the counter
bioelectronic device that is FDA approved for the treatment of
symptoms of inflammation such as sinus pain and congestion. Tivic
has proven its ability to innovate by combining science and
technology with its expertise in neuroimmunology, medical device
product development, and regulatory affairs. This patent filing is
Tivic’s first step towards targeting life-threatening or
irreversibly debilitating human diseases or conditions that have
high costs and could benefit from more effective, patient-centric
therapeutic solutions.
Read more about the Function and Benefits of Stimulating the
Vagus Nerve here.
About Tivic
Tivic Health Systems, Inc. is a commercial-phase health
technology company delivering non-invasive bioelectronic treatments
that provide consumers with a choice in the treatment of
inflammation and related conditions. For more information visit
https://tivichealth.com @TivicHealth.
Forward-Looking Statements
This press release may contain “forward-looking statements” that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
“will” “would,” or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on Tivic Health
Systems, Inc.’s current expectations and are subject to inherent
uncertainties, risks, and assumptions that are difficult to
predict. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Actual results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: the issuance of the new patent by
the USPTO; clinical trial results; FDA approval of any product
developed based on the filed patent; market and other conditions;
supply chain constraints; macroeconomic factors, including
inflation; and unexpected costs, charges or expenses that reduce
Tivic’s capital resources. Given these risks and uncertainties, you
are cautioned not to place undue reliance on such forward-looking
statements. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause Tivic’s actual
results to differ from those contained in the forward-looking
statements, see Tivic’s filings with the SEC, including, its Annual
Report on Form 10-K for the year ended December 31, 2022, filed
with the SEC on March 31, 2023, under the heading “Risk Factors”;
as well as the company’s subsequent filings with the SEC.
Forward-looking statements contained in this press release are made
as of this date, and Tivic Health Systems, Inc. undertakes no duty
to update such information except as required by applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230411005432/en/
Media Contact: Kayleigh Westerfield 949-632-3439
Kayleigh.Westerfield@tivichealth.com
Investor Contact: Hanover International, Inc.
ir@tivichealth.com
Tivic Health Systems (NASDAQ:TIVC)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tivic Health Systems (NASDAQ:TIVC)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024